The role of the VEGF family in coronary heart disease
Y Zhou, X Zhu, H Cui, J Shi, G Yuan, S Shi… - Frontiers in …, 2021 - frontiersin.org
The vascular endothelial growth factor (VEGF) family, the regulator of blood and lymphatic
vessels, is mostly investigated in the tumor and ophthalmic field. However, the functions it …
vessels, is mostly investigated in the tumor and ophthalmic field. However, the functions it …
Clinical development of targeted and immune based anti-cancer therapies
Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …
angiogenic growth factors, including members of the vascular endothelial growth factor …
Trends and challenges in tumor anti-angiogenic therapies
J Jászai, MHH Schmidt - Cells, 2019 - mdpi.com
Excessive abnormal angiogenesis plays a pivotal role in tumor progression and is a
hallmark of solid tumors. This process is driven by an imbalance between pro-and anti …
hallmark of solid tumors. This process is driven by an imbalance between pro-and anti …
Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non …
PM Lacal, G Graziani - Pharmacological research, 2018 - Elsevier
The vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor
for VEGF-A, VEGF-B, and placental growth factor (PlGF) ligands that is expressed in …
for VEGF-A, VEGF-B, and placental growth factor (PlGF) ligands that is expressed in …
Angiogenesis in the infarcted myocardium
Significance: Proangiogenic therapy appeared a promising strategy for the treatment of
patients with acute myocardial infarction (MI), as de novo formation of microvessels, has the …
patients with acute myocardial infarction (MI), as de novo formation of microvessels, has the …
Vascular endothelial growth factor in heart failure
Heart failure is a devastating condition, the progression of which culminates in a mismatch of
oxygen supply and demand, with limited options for treatment. Heart failure has several …
oxygen supply and demand, with limited options for treatment. Heart failure has several …
Postischemic revascularization: from cellular and molecular mechanisms to clinical applications
After the onset of ischemia, cardiac or skeletal muscle undergoes a continuum of molecular,
cellular, and extracellular responses that determine the function and the remodeling of the …
cellular, and extracellular responses that determine the function and the remodeling of the …
Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia
M Silasi, B Cohen, SA Karumanchi… - … and Gynecology Clinics, 2010 - obgyn.theclinics.com
Preeclampsia (PE) is a disorder occurring after week 20 of pregnancy and marked by
hypertension and proteinuria. It is the major cause of maternal and fetal morbidity worldwide …
hypertension and proteinuria. It is the major cause of maternal and fetal morbidity worldwide …
Vascular endothelial growth factor-B in physiology and disease
M Bry, R Kivelä, VM Leppänen… - Physiological …, 2014 - journals.physiology.org
Vascular endothelial growth factor-B (VEGF-B), discovered over 15 years ago, has long
been seen as one of the more ambiguous members of the VEGF family. VEGF-B is produced …
been seen as one of the more ambiguous members of the VEGF family. VEGF-B is produced …